U.S. Paper and Forestry Products Stock News

Eton Pharmaceuticals (ETON) just posted its FY 2025 Q4 numbers with revenue of US$21.3 million and Basic EPS of US$0.06, while the trailing twelve months show revenue of US$80.0 million and a Basic EPS loss of US$0.17. Over recent quarters, the company has seen quarterly revenue move from US$11.6 million in Q4 2024 to US$21.3 million in Q4 2025, alongside Basic EPS shifting from a loss of US$0.02 in Q4 2024 to a profit of US$0.06 in Q4 2025. This sets up a results season where investors will...

Canadian Solar (CSIQ) has capped FY 2025 with fourth quarter revenue of US$1.2 billion and a basic EPS loss of US$1.28, as net income excluding extra items came in at a loss of US$86.3 million, putting the spotlight firmly on profitability rather than top line scale. Over recent quarters, the company has seen revenue move between US$1.2 billion and US$1.7 billion, with basic EPS swinging from a profit of US$0.51 in Q4 2024 to a loss in Q4 2025. This sets up a results season where margin...

Alumis (ALMS) has just wrapped up FY 2025 with Q4 revenue of US$1.9 million, a basic EPS loss of US$0.89 per share, and a net loss of US$92.9 million. On a trailing twelve month basis, revenue was US$24.1 million, with a basic EPS loss of US$2.86 per share and a net loss of US$243.3 million. Over recent quarters, revenue moved from US$17.4 million in Q1 2025 to US$2.7 million in Q2, US$2.1 million in Q3, and US$1.9 million in Q4. EPS shifted from a loss of US$1.82 in Q1 to a profit of US$0.78...

Fortune Brands Innovations (NYSE:FBIN) has appointed an interim CEO and an interim CFO while launching a formal search for a permanent chief executive. The company reached a governance cooperation agreement with activist investor Ed Garden, who has joined the board of directors. The board plans to phase out its classified structure, following internal leadership changes and shareholder pressure that appear aimed at avoiding a proxy fight. For investors watching NYSE:FBIN, these leadership...

Assembly Biosciences (ASMB) just closed FY 2025 with Q4 revenue of US$42.5 million and basic EPS of US$1.30, alongside trailing twelve month revenue of US$72.3 million and a trailing EPS loss of US$0.55. Over recent quarters the company has seen revenue move from US$7.4 million and an EPS loss of US$1.58 in Q4 FY 2024 to US$42.5 million and EPS of US$1.30 in Q4 FY 2025, while trailing twelve month net income narrowed to a loss of US$6.1 million. This sets up a results season where investors...

Gold Royalty (NYSEAM:GROY) recently reported three consecutive quarters of positive free cash flow, which management has described as a financial inflection point. The company reported record annual revenue and cash flow, alongside a shift to a zero-debt capital structure after equitizing debt and completing a major equity raise. Gold Royalty expanded its portfolio with a new royalty on BHP's Pedra Branca mine, adding exposure to an operating asset. Gold Royalty, which last closed at $3.15,...

HF Sinclair plans a permanent separation with its CEO and CFO following their voluntary leaves. The company is working toward final separation agreements as part of an ongoing internal review. The dual executive exit comes during a period of growth that includes joint ventures and other initiatives. For HF Sinclair (NYSE:DINO), this leadership change comes at a time when the stock has seen strong recent performance, with shares at $60.22 and a 28.5% return year to date. The stock is up 8.1%...

Sky Harbour Group (SKYH) closed FY 2025 with Q4 revenue of US$8.1 million and basic EPS of US$0.28, alongside trailing twelve month revenue of US$27.5 million and EPS of US$0.56 that reflect the recent shift into profitability. The company has seen quarterly revenue move from US$4.6 million in Q4 2024 to US$8.1 million in Q4 2025, while basic EPS has swung from a loss of US$0.47 to a profit of US$0.28 over the same period. This gives investors a clearer view of how top line scale and earnings...

Wondering if TXNM Energy at around US$58 is offering value or asking too much? This article breaks down what the current price might really mean for you. The stock has seen a 1.3% decline over the last 7 days and is down 2.0% over the past month, while still showing a 10.7% return over 1 year and 32.2% over 3 years. Recent coverage of TXNM Energy has focused on its positioning within the Electric Utilities space and how investors are reacting to the current pricing and sector sentiment. This...

Datavault AI (DVLT) closed out FY 2025 with fourth quarter revenue of US$33.8 million and basic EPS of roughly US$0.00, while trailing twelve month revenue stood at US$39.1 million and basic EPS reflected a loss of US$0.52. Over recent quarters, the company has seen revenue move from US$0.9 million in Q4 2024 to US$33.8 million in Q4 2025, as quarterly EPS shifted from a loss of US$2.00 to around breakeven. This sets up a results season where rapid top line expansion sits alongside still...

Micron Technology (MU) has put up a big quarter, with Q2 2026 revenue of about US$23.9b, basic EPS of US$12.24 and net income of roughly US$13.8b. These figures feed into trailing 12 month EPS of US$21.49 on revenue of about US$58.1b and net income of roughly US$24.1b, alongside very large year over year earnings growth. The company has seen quarterly revenue move from US$8.1b and EPS of US$1.42 in Q2 2025 to US$23.9b and EPS of US$12.24 in Q2 2026. Over the same period, trailing net profit...

Ormat Technologies (NYSE:ORA) has priced $875 million of convertible senior notes in a significantly upsized offering. The company plans to use the proceeds to repurchase existing debt and shares, reshaping its capital structure. The transaction introduces new convertible securities that can affect future dilution and interest costs for shareholders. For readers tracking NYSE:ORA, this financing move comes with the stock at $110.52 and a 1 year return of 54.2%. Over 3 and 5 years, returns...

Edwards Lifesciences (NYSE:EW) has appointed Niranjan Pai as Director, Government Affairs. The new appointment places an experienced policy professional in a role focused on public policy and regulatory engagement. For investors tracking Edwards Lifesciences at a share price of $82.46, this move adds another piece to the broader picture around NYSE:EW. The company’s 1 year return of 16.2% sits alongside more modest 3 year and 5 year returns of 3.7% and 2.4%, which may prompt readers to pay...

Village Farms International reported fourth-quarter 2025 sales of US$49.62 million and net income of US$2.43 million, alongside full-year 2025 sales of US$215.94 million and net income of US$32.44 million, marking a shift from losses a year earlier. Over the same period, the company completed a repurchase of 812,923 shares for US$2.98 million, which, combined with the earnings turnaround, highlights management’s emphasis on improving profitability while also returning capital to...

ESAB Corporation (NYSE:ESAB) has priced a US$1b senior notes offering to fund the acquisition of Eddyfi Holding Inc. The deal is structured as a debt financed transaction, with the notes backed by guarantees from ESAB subsidiaries. This move follows a period of slower organic sales growth and reflects management’s focus on acquisitions to support expansion. ESAB, known for welding, cutting and gas control equipment, is moving to add Eddyfi’s testing and inspection capabilities to its...

W.W. Grainger (NYSE:GWW) has been named one of the 2026 World's Most Ethical Companies by Ethisphere. This is Grainger's second consecutive year receiving the recognition. The award highlights the company's focus on corporate governance, ethics, and responsible business practices. For investors following NYSE:GWW, this recognition comes on top of its role as a major distributor of maintenance, repair, and operating products to businesses and institutions. Ethical credentials can be...

Event context and recent share performance TEGNA (TGNA) shares recently closed at US$20.03, with the stock showing a roughly 1.3% decline over the past day, a 0.9% decline over the past week, and a 4.1% decline over the past month. See our latest analysis for TEGNA. While the recent 1 month share price return of a 4.1% decline has cooled momentum, the 1 year total shareholder return of 9.5% and 3 year total shareholder return of 39.5% point to a stronger longer term record. If you are...

Wondering whether SkyWest's current share price reflects its true value, or if the market is mispricing the stock. SkyWest recently closed at US$89.36, with a 0.2% decline over 7 days, a 16.8% decline over 30 days, an 11.7% decline year to date, a 1.1% decline over 1 year, a very large gain over 3 years and a 66.0% gain over 5 years, which may have caught your attention. Recent price moves sit against a backdrop where investors are reassessing airlines and regional carriers in light of...

CytomX Therapeutics recently reported full-year 2025 results showing sales of US$76.2 million and a net loss of US$17.37 million, and has just raised roughly US$250.00 million through a follow-on offering of common stock and pre-funded warrants at about US$5.30 per security. At the same time, the company released encouraging Phase 1 data for its EpCAM-targeted ADC Varseta-M in heavily pretreated metastatic colorectal cancer, with a high disease control rate and a safety profile that appears...

Titan America (NYSE:TTAM) has agreed to acquire Keystone Cement, expanding its presence and capacity in the Mid-Atlantic region. The company reports record revenue, EBITDA and operating cash flows for 2025, despite sector headwinds. These developments have not yet been widely discussed and may reshape Titan America's growth profile and operational footprint. For investors tracking NYSE:TTAM, the stock last closed at $14.71, with a 1 year return of 15.1% and a 12.0% decline year to date...

Why Protalix BioTherapeutics is Back on Investors’ Radar Protalix BioTherapeutics (PLX) has drawn fresh attention after the European Commission approved a new Elfabrio dosing regimen for certain Fabry disease patients, alongside updated 2026 revenue guidance that includes a US$25 million regulatory milestone. See our latest analysis for Protalix BioTherapeutics. The Elfabrio dosing news and 2026 guidance update arrive after a mixed share price pattern, with a 28.9% 90 day share price return...

Ovid Therapeutics (OVID) has drawn fresh attention after reporting Phase 1 data for its OV329 epilepsy program at a 7 mg dose, alongside plans to expand into new seizure indications backed by about US$60 million in private financing. See our latest analysis for Ovid Therapeutics. The new OV329 data and US$60 million financing arrive after a sharp run in the stock, with a 30 day share price return of 60.84% and a 1 year total shareholder return above 400%, even though the 3 year and 5 year...

Collegium Pharmaceutical (NasdaqGS:COLL) has entered into a definitive agreement to acquire AZSTARYS. The deal expands Collegium’s ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings. The transaction is described as immediately accretive to adjusted EBITDA. For investors following the ADHD treatment space, this move provides another data point on how branded therapies are being repositioned. Collegium, which focuses on pain and ADHD treatments, is adding...

Globant (NYSE:GLOB) announced an AI focused collaboration with PharmaMar to support cancer drug discovery efforts. The company also agreed a global integration partnership with payments platform Adyen for enterprise clients. Both arrangements position Globant in healthcare and fintech projects tied to drug research and digital payments infrastructure. Globant operates as a digital services and technology company, working with enterprises that are investing in cloud, data and AI based...